The Cambrian Alliance Group and Target Healthcare are pleased to announce that they have
entered into a new supply agreement for the provision of generic and PI medicines to independent
pharmacy across the UK. This new supply agreement combines Cambrian’s market leading buying
platform, e-CASS, with Target’s first class delivery service and supply arrangements.

With supply disruption and price volatility playing such a critical role in the procurement of
medicines in the UK recently, independent pharmacies are increasingly looking to identify
alternative supply arrangements and seek out improved levels of service from wholesalers.

The new supply agreement brings together Cambrian’s technical expertise and experience of
supporting independent contractors to improve margin, alongside Target’s unparalleled reputation
for service, next day deliveries and competitive pricing.

“This new supply agreement is well timed and will be particularly welcomed by independent
contractors concerned with securing supply and ensuring next day delivery of products for their
patients,” said Nathan Wiltshire, Cambrian Alliance’s Group CEO.

“We believe Target will be an excellent addition to our portfolio of suppliers and we look forward to assisting our customers in achieving greater levels of profitability as well as supporting Target with their growth aspirations.”

Commenting on the new partnership, Target’s Managing Director, Lewis Campbell said,

“We are really excited to be working with Cambrian and look forward to being able to support their
customers during such a difficult period for independent pharmacy in the UK. We have been
selected by Cambrian as a result of our consistent service and ability to utilise our own van
network, meaning that on average, 99% of all orders achieve next day delivery.”

Healthcare Professional ONLY
This website is intended for Healthcare professionals only

Are you a qualified pharmacist or health professional?
By continuing to access this site, you are consenting to viewing promotional product information provided by our pharmaceutical company sponsors